©
Cimmerian
iStockphoto
Rituximab plus lenalidomide as a potential firstline option
Jatros Digital
30
Min. Lesezeit
15.06.2018
Weiterempfehlen
<p class="article-intro">RELEVANCE is the first clinical trial comparing lenalidomide plus rituximab versus standard chemoimmunotherapy followed by rituximab maintenance in untreated FL patients. </p>
<hr />
<p class="article-content"><p>Chemoimmunotherapy (R-chemo) induction followed by rituximab maintenance is the standard of care in previously untreated, symptomatic follicular lymphoma (FL). Lenalidomide is an immunomodulatory agent with complementary mechanisms when combined with rituximab (R<sup>2</sup>).</p> <p>RELEVANCE is the first randomized phase III superiority comparison of the immunomodulatory regimen R<sup>2</sup> versus standard R-chemo, followed by rituximab maintenance, in previously untreated patients with advanced FL requiring treatment. There were 1030 patients randomized 1:1 who received treatment for a total duration of 120 weeks. The study had 2 co-primary endpoints of complete response (CR/CRu) at 120 weeks and progression-free survival (PFS; first interim analysis at 50 % of events). Both groups had similar baseline characteristics.</p> <p>Superiority for R<sup>2</sup> over R-chemo was not established for either co-primary endpoint. At a median follow-up of 37,9 months, CR/CRu at 120 weeks was similar in the respective R<sup>2</sup> versus R-chemo groups (48 % vs. 53 % ), and 3-year PFS rates were 77 % versus 78 % . The 3-year overall survival rates were high for both arms at 94 % .</p> <p>The safety profiles for R<sup>2</sup> versus R-chemo were different. Higher grade 3/4 neutropenia (34 % vs. 50 % ) and febrile neutropenia (2 % vs. 6 % ) were associated with R-chemo, and higher grade 3/4 cutaneous reactions (7 % vs. 1 % ) were associated with R<sup>2</sup>. Second primary malignancies were reported in 7 % of R<sup>2</sup> patients and 9 % of R-chemo patients and grade 5 adverse events were 1 % in both arms.</p> <p>In summary, RELEVANCE is the first randomized phase-III-trial comparing R<sup>2</sup> versus standard R-chemo, followed by rituximab maintenance, in previously untreated patients with FL. R<sup>2</sup> and R-chemo showed similar efficacy with a different safety profile. These results show that R<sup>2</sup>, a novel immunomodulatory approach, is a potential first-line option for FL patients requiring treatment.</p> <p><strong>Reference:</strong> <br /> <em>Morschhauser F et al.: RELEVANCE: phase III efficacy and safety study of lenalidomide plus rituximab (R2) versus rituximab plus chemotherapy, followed by rituximab, in previously untreated follicular lymphoma. EHA Annual Congress, abstract # S154</em></p></p>
Das könnte Sie auch interessieren:
Hinweise auf schlechteren Verlauf bei Männern bestätigt
Obwohl Frauen häufiger an einer Lupusnephritis erkranken, scheint diese bei Männern schwerer zu verlaufen. Diese Hypothese wird von einer Metaanalyse der Universität Minnesota unterstützt.1 Männer bekamen häufiger eine Nephritis vom Grad IV ± V, hatten schlechtere Nierenparameter und eine geringere Wahrscheinlichkeit für eine komplette Remission.
Le rôle de l’imagerie dans la sarcoïdose cardiaque
La sarcoïdose cardiaque est une maladie cardiaque inflammatoire rare, mais importante. Le tableau clinique peut être très variable, allant de manifestations subcliniques à une gêne ...
Frühe, aggressive Therapie ist entscheidend
Frauen erkranken zwar häufiger an einer Lupusnephritis, aber Studien weisen darauf hin, dass die Krankheit bei Männern schwerer verläuft. Diese Hypothese wird durch eine neue Metaanalyse ...